Background: Biofilm-associated Pseudomonas aeruginosa infections in cystic fibrosis have limited treatment options. Ceftolozane/tazobactam is a relatively recently available β-lactam/β-lactamase inhibitor combination that has been shown to have preserved activity against difficult-to-treat P. aeruginosa isolates. However, the effectiveness of ceftolozane/tazobactam (C/T), in monotherapy and combination with tobramycin (TOB), has not yet been characterised for the pharmacokinetics […]
2023
Preliminary development of a semi physiologically-based pharmacokinetic model for rocuronium
Introduction: Rocuronium is commonly used to temporarily paralyse the muscles of the jaw and voice box to facilitate intubation. In the first few minutes after rapid IV administration, cardiac output (CO) is a primary determinant of arterial blood concentrations, and thus effect, for many drugs. In particular, CO can be significantly altered in emergency patients. […]
Pharmacokinetics and Pharmacodynamics of TU2670 (nonpeptide GnRH antagonist) in healthy female subjects
OBJECTIVE: TU2670 is a novel competitive pituitary GnRH receptor antagonist to treat endometriosis. We investigated the safety, tolerability, pharmacokinetics and pharmacodynamics of TU2670 after multiple oral administration in healthy female subjects. Population PK/PD analysis using pooled phase I clinical trial data was also performed to suggest efficacious doses to treat endometriosis. DESIGN: Phase I, single-blind, […]